01605nam a2200241   4500001000800000005001700008007000300025008004100028040000800069041000800077100003500085245002600120300002500146520089800171650003201069650003201101650004201133650001601175650002701191650001801218650002401236773010301260ESSALUD20260903155458.0ta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aFitzgerald, Rebecca C. eAutor  aBarrett’s Esophagus  apáginas: 1723-1735  aBarrett’s esophagus develops as a result of chronic acid and bile reflux and carries an increased risk of esophageal adenocarcinoma. Because it has no specific symptoms, many patients do not receive a diagnosis or they present with symptoms of gastroesophageal reflux disease and other related risk factors or complications. Diagnosis relies on endoscopic and histopathological findings, including a visible columnar-cell–lined segment measuring at least 1 cm long that contains intestinal metaplasia with goblet cells. Ongoing surveillance focuses on early detection of malignant progression, particularly high-grade dysplasia and early-stage cancer, which allows curative endoscopic treatment and avoids the adverse effects associated with chemotherapy or esophagectomy. Participation in clinical trials is encouraged to improve detection, risk stratification, and management strategies.  aGASTROENTEROLOGÍA GENERAL  aTRATAMIENTOS EN ONCOLOGÍA  aCÁNCER DEL TRACTO GASTROINTESTINAL   aGERIATRÍA  aENVEJECIMIENTO GENERAL  aHEMATOLOGÍA  aONCOLOGÍA GENERAL0 022717dMassachusetts NEJM GroupoNEJM016tThe New England Journal of Medicine wESSALUDx0028-4793